Xoma Investor Relations Material
Latest events
Status Update
Xoma
Q1 2025
24 Apr, 2025
Status Update
26 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Xoma
Access all reports
XOMA Corporation is a biotechnology company focused on licensing and royalty acquisitions related to commercial and late-stage pharmaceutical assets. The company does not develop or market its own products but instead acquires rights to future royalty streams and milestone payments associated with therapeutic candidates developed by other companies. XOMA’s portfolio includes interests in various drug candidates across multiple therapeutic areas. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Latest articles
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
Ticker symbol
XOM
Country
🇸🇪 Sweden